The rationale for use of topical corticosteroids in allergic rhinitis
- 1 May 1996
- journal article
- congress
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 26 (s3) , 2-10
- https://doi.org/10.1111/j.1365-2222.1996.tb00652.x
Abstract
Summary: The rationale for using topical corticosteroids in the treatment of allergic rhinitis is that high drug concentrations can be achieved at receptor sites in the nasal mucosa, with minimal risk of systemic adverse effects. Topical corticosteroids have been demonstrated to reduce the number of Langerhans' cells (or their markers) in the nasal mucosa, and this is thought to attenuate antigen presentation. T lymphocytes have been identified as being significant in orchestrating the immune‐inflammatory response, particularly the TH2 cells, which represent an important target for topical corticosteroids. TH2 cell‐evoked mast cells and basophils are the sole producers of histamine, a mediator of major importance for rhinitis symptoms. Several studies have shown that the increased number of mast cells and basophils in the epithelium following antigen challenge/exposure, are markedly reduced by topical corticosteroids. Furthermore, the number of eosinophils, an important morphological marker of allergic rhinitis, can be profoundly reduced by treatment with topical corticosteroids. The rationale for topical treatment is strengthened by evidence of inhibition of cytokine release from surface epithelial cells, resulting in reduced recruitment and activation of mast cells, basophils, and eosinophils, which may be attributed to the high drug concentration achieved in epithelial cells. Ongoing inflammation in the mucous membrane is indicated by entry of plasma into the nasal lumen which subsides with the anti‐inflammatory efficacy of topical corticosteroids. In contrast to anlihistamine therapy, which has little effect on nasal blockage, pretreatment with topical corticosteroids results in almost complete attenuation of late‐phase symptoms including nasal blockage, and moderate efficacy in early phase symptoms. Clearly, the spectrum of anti‐inflammatory activity afforded by topical corticosteroid therapy is of clinical significance in reducing the three major symptoms of allergic rhinitis — sneezing, watery rhinorrhoea and nasal blockage.Keywords
This publication has 38 references indexed in Scilit:
- Effect of 3 months’ nasal steroid therapy on nasal T cells and Langerhans cells in patients suffering from allergic rhinitisAllergy, 1995
- Basophils and eosinophils in allergic rhinitisJournal of Allergy and Clinical Immunology, 1994
- Glucocorticoid-induced attenuation of mucosal exudation of fibrinogen and bradykinins in seasonal allergic rhinitisAllergy, 1994
- Plasma exudation as a first line respiratory mucosal defenceClinical and Experimental Allergy, 1991
- A Randomized Controlled Trial of Glucocorticoid Prophylaxis against Experimental Rhinovirus InfectionThe Journal of Infectious Diseases, 1990
- Allergen-induced increase of eosinophil cationic protein in nasal lavage fluid: Effect of the glucocorticoid budesonideJournal of Allergy and Clinical Immunology, 1990
- Characterization and Quantification of Cellular Infiltrates in Nasal Mucosa of Patients with Grass Pollen Allergy, Non-Allergic Patients with Nasal Polyps and ControlsInternational Archives of Allergy and Immunology, 1990
- Inhibition of Mediator Release in Allergic Rhinitis by Pretreatment with Topical GlucocorticosteroidsNew England Journal of Medicine, 1987
- Local Effect of Intranasal Beclomethasone Dipropionate Aerosol in Hay FeverBMJ, 1973
- Quantitative intranasal pollen challengesJournal of Allergy, 1969